Sotera Health (SHC) Financials

Sotera Health’s Q2 2026 results show a meaningful improvement in operating performance compared with the same quarter in 2025. Revenue increased 9.2% to $321.4 million, while operating income rose 20.8% to $106.8 million. Net income attributable to common shareholders climbed to $53.6 million from $8.0 million, lifting diluted EPS to $0.19 from $0.03.

The company’s gross margin remained strong at approximately 55.4%, although it was modestly below the 56.6% recorded in Q2 2025. The operating margin improved to 33.2% from 30.1%, indicating that operating expenses grew more slowly than revenue. Results also improved sequentially: Q2 revenue rose from $280.0 million in Q1 2026, while net income more than doubled from $26.6 million.

Cash generation was another strong point. Operating cash flow increased to $88.5 million in Q2 2026 from $57.4 million in Q2 2025 and $29.4 million in Q1 2026. After $46.4 million of capital expenditures, estimated free cash flow was approximately $42.0 million, compared with roughly $26.2 million a year earlier. However, capital spending remains substantial, consuming more than half of quarterly operating cash flow.

The balance sheet also improved from the prior-year period. Cash and equivalents increased to $356.7 million from $332.4 million, while total debt including capital lease obligations declined to approximately $2.24 billion from $2.32 billion. Total equity increased to $665.6 million from $511.3 million, helped by stronger retained earnings and a reduction in accumulated comprehensive losses. Current assets exceeded current liabilities by approximately 2.8 times at the end of Q2 2026.

• Revenue growth accelerated: Q2 2026 revenue rose 9.2% year over year and 14.8% sequentially, continuing the improvement from $220.6 million in Q1 2023 to $321.4 million in Q2 2026.
• Profitability improved substantially: Operating income reached $106.8 million, and the operating margin expanded to approximately 33.2% despite a slightly lower gross margin.
• Net income and EPS rebounded: Net income increased to $53.6 million from $8.0 million in Q2 2025, while diluted EPS rose to $0.19 from $0.03.
• Operating cash flow strengthened: Quarterly operating cash flow of $88.5 million was the strongest level in the supplied 2026 data and exceeded the Q2 2025 figure by more than $31 million.
• Free cash flow turned stronger: After capital expenditures, Q2 2026 generated approximately $42 million of free cash flow, reversing the estimated negative free cash flow reported in Q1 2026.
• Liquidity improved: Cash increased by approximately $24.3 million year over year, and total current assets rose to $646.5 million from $608.2 million in Q2 2025.
• Debt declined modestly: Total debt and capital lease obligations were approximately $82 million lower than in Q2 2025, while the company continued making debt repayments.
• Historical earnings have been volatile: Sotera Health reported losses in Q3 2023 and Q1 2025, but returned to profitability in subsequent quarters. Investors should assess whether the recent improvement is sustainable.
• Leverage remains high: Long-term debt was approximately $2.13 billion at quarter-end, and total liabilities of $2.64 billion were nearly four times shareholders’ equity.
• Capital requirements remain heavy: Q2 2026 capital expenditures totaled $46.4 million, and cumulative spending over the recent quarters has limited the amount of operating cash available for debt reduction or other shareholder-oriented uses.

Overall, the statements point to a stronger near-term financial profile, with accelerating revenue, improved operating margins, better cash conversion and gradual debt reduction. The primary risks are Sotera Health’s substantial leverage, recurring capital spending and historically uneven earnings. The supplied income statements also include several restated or calculated periods, so investors should confirm unusual line items and compare future filings on a consistent basis.